In this article by Contract Pharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses how the CDMO is positioning itself to stay ahead of the curve and what are the most significant trends in the CDMO industry.
Thierry also talks about the business highlights from the past 12-24 months and how the Quotient Sciences is integrating new technologies and innovations in its processes.
Continue reading the full article or watching the video on Contract Pharma.